The speed with which the US Food and Drug Administration reviewed and authorized Pfizer Inc.’s COVID-19 treatment Paxlovid may say as much about the agency’s confidence in the antiviral as it does about concerns with Merck & Co., Inc.’s oral antiviral molnupiravir, which was submitted weeks earlier and appears to still be under review.
On 22 December, the FDA granted emergency use authorization to Paxlovid for the treatment of mild-to-moderate COVID-19 in adults and...






